Sign in
BS

Brookdale Senior Living Inc. (BKD)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 delivered top-end RevPAR growth (5.5% YoY) and an Adjusted EBITDA beat vs company guidance; consolidated occupancy rose 100 bps YoY and 50 bps sequentially, while net loss widened sequentially on a $15.5M debt extinguishment loss and higher facility OpEx tied to hurricanes .
  • 2025 outlook: RevPAR +4.75% to +5.75% and Adjusted EBITDA $430–$445M, with step-down in cash lease payments once 55 Ventas communities are transitioned/sold; full-year Adjusted FCF expected to be “meaningfully positive” .
  • Structural catalysts executed: Ventas lease amendment removes a negative-cash-flow portfolio and extends 65 higher-performing communities to 2035; 2027 maturities proactively refinanced and converts extended to 2029, improving liquidity (Q4 total liquidity $389M) .
  • Demand tailwinds intact; management highlighted recovery in paid lead sources, best Q4 move-ins since 2016, and programmatic differentiation (HealthPlus) supporting longer length of stay and higher satisfaction—key narrative for 2025 occupancy/EBITDA momentum .

What Went Well and What Went Wrong

  • What Went Well

    • RevPAR and EBITDA outperformance: Q4 RevPAR +5.5% YoY at top of guidance and Adjusted EBITDA +15.5% YoY, above the prior range .
    • Occupancy and move-ins: Weighted average occupancy +100 bps YoY and +50 bps sequentially; Q4 move-ins strongest since 2016, and January occupancy sequential performance exceeded pre-pandemic seasonality .
    • Strategic portfolio/capital actions: Ventas lease amendment “solved the single largest capital structure issue” and expected to improve 2025 cash flow by $15M+; 2027 mortgage debt refinanced at 6.14% fixed, and 2026 converts largely exchanged into 2029 notes .

  • What Went Wrong

    • Sequential net loss widened: Net loss of $(83.9)M vs $(50.7)M in Q3 due to a $15.5M loss on debt extinguishment and higher facility OpEx (insurance, hurricanes) .
    • Legal and natural disaster costs: Q4 G&A included $7.0M legal expense for putative class action litigation; natural disaster expense was ~$3.5M in Q4 (Hurricanes Helene/Milton) .
    • Lead flow disruption persisted much of 2024 (two large third-party referrers), weighing on occupancy vs plans; redeployed spend to internal/hyper-local channels, with improving trends into Q4/January .

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Resident Fees ($M)$739.7 $743.7 $744.4
Total Revenue and Other Operating Income ($M)$777.5 $784.2 $780.9
Adjusted EBITDA ($M)$97.8 $92.2 $98.5
GAAP Diluted EPS (Loss/Share)$(0.17) $(0.22) $(0.37)
Combined Segment Operating Margin (%)27.6% 26.5% 25.7%
RevPAR ($)$4,835 $4,869 $4,873
RevPOR ($)$6,193 $6,171 $6,136
Weighted Avg Occupancy (%)78.1% 78.9% 79.4%

Segment performance (Senior Housing):

SegmentRevenue ($M) Q3 2024Revenue ($M) Q4 2024Operating Margin Q4 2023Operating Margin Q3 2024Operating Margin Q4 2024
Independent Living$150.4 $150.1 33.0% 32.4% 31.6%
Assisted Living & Memory Care$510.1 $510.5 25.6% 25.8% 25.1%
CCRCs$83.3 $83.8 15.9% 17.9% 16.9%

KPIs (Consolidated and Same Community):

KPIQ2 2024Q3 2024Q4 2024
Consolidated RevPAR ($)$4,835 $4,869 $4,873
Consolidated RevPOR ($)$6,193 $6,171 $6,136
Consolidated Occupancy (%)78.1% 78.9% 79.4%
Same-Community RevPAR ($)$4,826 $4,859 $4,866
Same-Community RevPOR ($)$6,177 $6,155 $6,121
Same-Community Occupancy (%)78.1% 78.9% 79.5%

Additional items:

  • Liquidity: $389.3M at 12/31/24 (cash $308.9M, $60.5M revolver availability, $19.9M marketable securities) .
  • Operating cash flow: $45.2M in Q4 (YoY +$15.9M) .
  • Adjusted FCF: $(11.5)M in Q4, improved YoY by $10.0M; H2 2024 aggregate positive per management .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevPAR YoY GrowthFY 2025N/A (initiated)4.75% – 5.75% New
Adjusted EBITDA ($M)FY 2025N/A (initiated)$430 – $445 New
Cash Facility Lease Payments ($M)Q1–Q3 2025 (each)N/A~ $57 per quarter; step down in Q4 assuming Oct 1 dispositions New
Non-Dev Capex ($M)FY 2025N/A$175 – $180 New
Q4 2024 RevPAR YoYQ4 20245.0% – 5.5% Actual: 5.5% (top end) Achieved at high end
Q4 2024 Adjusted EBITDA ($M)Q4 2024$93 – $98 Actual: $98.5 (above high end) Beat

Notes: FY25 guidance assumes previously announced acquisitions/dispositions and, for modeling, an Oct 1, 2025 disposition date for all 55 Ventas non-renewal communities .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024 and Q3 2024)Current Period (Q4 2024)Trend
Lead flow disruption and recoveryQ2/Q3: Disruption at two large third-party referrers; redeploying spend; occupancy growth continued but below plan Paid referrer rebound; strongest Q4 move-ins since 2016; January occupancy better than normal seasonality Improving
Labor and OpEx inflationModerating premium labor; OpEx pressure (insurance, utilities); outsourcing data centers increases expense classification Same-community labor % improved 40 bps YoY; other OpEx +50 bps YoY; hurricane costs impacted Q4 Mixed (labor improving, other OpEx pressured)
Portfolio optimization (Ventas/Omega; acquisitions)Q3: Announced acquisitions of 41 leased communities; Omega lease amendment; converts exchange Ventas amendment (exit 55 negative CF units; extend 65 to 2035), closed 11 Welltower assets, remaining acquisitions expected near-term Positive
Capital structure and liquidityQ2: No 2025 maturities without extensions; Q3: continued refinancing progress $344.2M Fannie Mae refinancing at 6.14% fixed; converts extended to 2029; eliminated 2025 maturities Positive
Clinical/technology programs (HealthPlus)Q3: Expanded HealthPlus communities Third-party analysis: 80% fewer ER/urgent care visits, 66% fewer hospitalizations vs similar seniors at home Positive differentiation
Seasonal illness/flu impact—Challenging flu season; mitigation via vaccination/infection control; no closures to date Manageable headwind

Management Commentary

  • CEO: “We delivered positive Adjusted Free Cash Flow in the back half of the year and have positioned the business to generate meaningful Adjusted Free Cash Flow in 2025…” .
  • CEO on Ventas: “I am very pleased that we have solved the single largest capital structure issue that Brookdale has faced in the last decade.” .
  • CFO: “This marked our 12th consecutive quarter of triple-digit year-over-year occupancy increases… fourth quarter adjusted EBITDA of approximately $99 million… above the top end of our guidance range once again.” .
  • CEO on HealthPlus: independent analysis found “80% fewer emergency room and urgent care visits and 66% fewer hospitalizations” for participants vs comparable seniors at home .
  • CFO on 2025: “We are pleased with our 2025 adjusted EBITDA expectations, which would result in 11% to 15% year-over-year growth… and… meaningfully positive adjusted free cash flow in 2025.” .

Q&A Highlights

  • RevPAR drivers and Ventas timing: FY25 RevPAR +4.75–5.75% bakes in lead flow recovery, seasonal flu risks, and assumes Oct 1 transition/sale of the 55 non-renewal Ventas communities; NOI and rent effects largely offset during transition .
  • Occupancy trajectory vs peers: BKD occupancy trails NIC benchmarks partly due to low Medicaid mix (~<4% vs industry ~18%) and conservative treatment of shared units; focus remains on profitable occupancy rather than raw occupancy targets .
  • EBITDA growth bridge: Midpoint implies fourth straight ~$50M YoY increase; growth from revenue flow-through, disciplined OpEx, and cash lease payment reduction from portfolio actions; hurricane/natural disaster modeling embedded .
  • G&A outlook and portfolio size: Expect 2025 G&A increase from merit and normalized incentives; management will appropriately align infrastructure post Ventas dispositions .

Estimates Context

  • Wall Street consensus: S&P Global estimates were unavailable due to access limits at the time of analysis; therefore, we cannot quantify beats/misses vs Street for Q4 or FY25. We benchmarked results vs company guidance instead (Q4 RevPAR hit top end; Adjusted EBITDA exceeded high end) .
  • Implications: Given FY25 Adjusted EBITDA guidance of $430–$445M and portfolio/lease actions, Street models below this range (if any) may need upward revision, particularly on lease expense cadence and occupancy flow-through .
  • Note: S&P Global consensus detail could not be retrieved; if needed, we can refresh once access is restored.

Key Takeaways for Investors

  • Execution beat: Q4 Adjusted EBITDA topped guidance and RevPAR hit the high end despite hurricane expenses and a debt extinguishment charge—evidence of strengthening fundamentals and cost control .
  • 2025 setup improved: Guidance implies 11–15% Adjusted EBITDA growth with a visible step-down in cash lease payments in Q4 as non-renewal Ventas assets exit, supporting a path to meaningfully positive full-year Adjusted FCF .
  • Portfolio quality mix up: Exiting 55 negative-cash-flow communities and extending 65 better-performing assets should enhance margin/FCF resilience and reduce lease risk through 2035 .
  • Occupancy momentum: Best Q4 move-ins since 2016 and improving January occupancy traction support an acceleration narrative into 2025 as lead channels normalize and HealthPlus expands .
  • Capital structure risk reduced: 2025 maturities eliminated; converts extended to 2029; $344.2M fixed-rate refi completed—liquidity rose to $389M at year-end .
  • Watch list: Other facility OpEx (insurance, utilities) and weather events; legal expense (Q4 had a $7M charge); flu/respiratory season impacts; cadence of Ventas transitions/sales .
  • Trading angle: The narrative pivot toward sustained EBITDA/FCF growth and reduced lease/debt overhang are likely stock catalysts; monitor occupancy prints and any Street estimate revisions post-guide .

Appendix: Additional Q4 Details

  • Drivers of sequential net loss increase: $15.5M loss on debt extinguishment (convertible notes transactions) and higher facility OpEx (insurance, hurricanes) .
  • Non-GAAP context: Q4 Adjusted EBITDA reconciliation reflects legal/transaction costs ($7.4M), operating lease expense adjustments, and stock-based comp; YoY Adjusted EBITDA +$13.2M .
  • Liquidity walk: Total liquidity increased $65.2M QoQ to $389.3M on financing/acquisition impacts and lower letters of credit .

Press release references and prior quarters:

  • Q3 2024: revenue/occupancy growth, positive Adjusted FCF ($13.9M), and guidance (Q4 RevPAR 5.0–5.5%; EBITDA $93–$98M) .
  • Q2 2024: RevPAR +6.4% YoY; moderating premium labor; detailed liquidity and non-GAAP reconciliations .

Estimates note: S&P Global consensus data could not be retrieved at this time due to access limitations.